Safety and efficacy of ustekinumab in adolescent patients with moderate to severe plaque psoriasis: Results through 1 year of the phase 3 CADMUS trial - 09/05/15
Ian Landells, MD, Memorial University of Newfoundland, St John’s, Newfoundland, Canada; Collen Marano, PhD, Janssen Research & Development, LLC, Spring House, PA, United States; Ming-Chun Hsu, PhD, Janssen Research & Development, LLC, Spring House, PA, United States; Shu Li, MS, Janssen Reserach & Development, LLC, Spring House, PA, United States; Lawrence Eichenfield, MD, University of California-San Diego, La Jolla, CA, United States; Peter Hoeger, MD, University of Hamburg, Catholic Children’s Hospital, Hamburg, Germany; Alan Menter, MD, Baylor University Medical Center, Dallas and Texas A&M Health Science Center School of Medicine, Dallas, TX, United States; Amy Paller, MD, Northwestern University Feinberg Medical School, Chicago, IL, United States; Alain Taieb, MD, Hôpital Saint André, University of Bordeaux, Bordeaux, France; Bruce Randazzo, MD, Janssen Research & Development, LLC, Spring House, PA, United States; Philippe Szapary, MD, Janssen Research & Development, LLC, Spring House, PA, United States
Le texte complet de cet article est disponible en PDF.| Study Sponsored by Janssen Research and Development. |
Vol 72 - N° 5S1
P. AB202 - mai 2015 Retour au numéro
Article précédent
- Phacomatosis cesiomarmorata associated with hypospadias and melanosis oculi: A rare case report
- Serving the underserved: Medicaid acceptance by US board-certified pediatric dermatologists
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?